The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance

BACKGROUND: Dysregulation of the canonical Wnt signaling pathway has been implicated in colorectal cancer (CRC) development as well as incipient stages of malignant transformation. In this study, we investigated the antitumor effects of AZ1366 (a novel tankyrase inhibitor) as a single agent and in c...

Descripción completa

Detalles Bibliográficos
Autores principales: Quackenbush, Kevin S., Bagby, Stacey, Tai, Wai Meng, Messersmith, Wells A., Schreiber, Anna, Greene, Justin, Kim, Jihye, Wang, Guoliang, Purkey, Alicia, Pitts, Todd M., Nguyen, Anna, Gao, Dexiang, Blatchford, Patrick, Capasso, Anna, Schuller, Alwin G., Eckhardt, S. Gail, Arcaroli, John J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053726/
https://www.ncbi.nlm.nih.gov/pubmed/27070088
http://dx.doi.org/10.18632/oncotarget.8626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053726/
https://www.ncbi.nlm.nih.gov/pubmed/27070088
http://dx.doi.org/10.18632/oncotarget.8626

Ejemplares similares